- Home
- CALC vs DTIL Comparison
CALC vs DTIL Comparison
Compare CALC & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- DTIL
- Stock Information
- Founded
- CALC 2011
- DTIL 2006
- Country
- CALC United States
- DTIL United States
- Employees
- CALC N/A
- DTIL N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- DTIL Health Care
- Exchange
- CALC Nasdaq
- DTIL Nasdaq
- Market Cap
- CALC 48.1M
- DTIL 55.3M
- IPO Year
- CALC N/A
- DTIL 2019
- Fundamental
- Price
- CALC $2.91
- DTIL $4.71
- Analyst Decision
- CALC Strong Buy
- DTIL Strong Buy
- Analyst Count
- CALC 2
- DTIL 2
- Target Price
- CALC $14.50
- DTIL $47.00
- AVG Volume (30 Days)
- CALC 91.2K
- DTIL 167.1K
- Earning Date
- CALC 08-12-2025
- DTIL 08-07-2025
- Dividend Yield
- CALC N/A
- DTIL N/A
- EPS Growth
- CALC N/A
- DTIL N/A
- EPS
- CALC N/A
- DTIL N/A
- Revenue
- CALC N/A
- DTIL $1,261,000.00
- Revenue This Year
- CALC N/A
- DTIL N/A
- Revenue Next Year
- CALC N/A
- DTIL $53.21
- P/E Ratio
- CALC N/A
- DTIL N/A
- Revenue Growth
- CALC N/A
- DTIL N/A
- 52 Week Low
- CALC $1.42
- DTIL $3.61
- 52 Week High
- CALC $5.97
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- CALC 52.85
- DTIL 50.82
- Support Level
- CALC $2.31
- DTIL $4.27
- Resistance Level
- CALC $3.00
- DTIL $5.13
- Average True Range (ATR)
- CALC 0.34
- DTIL 0.32
- MACD
- CALC -0.12
- DTIL -0.01
- Stochastic Oscillator
- CALC 40.00
- DTIL 53.33
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.